-
-
-
-
-
-
-
Lilly's Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays
-
-
-
-
-
-
-
Eli Lilly (LLY) PT Lowered to $$1,058 at Leerink Partners
-
-
-
-
-
-
-
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
-
-
-
-
-
-
-
Eli Lilly to acquire Orna Therapeutics for up to $2.4 billion
-
-
-
-
-
-
-
Eli Lilly earnings preview Q4: strong print expected on obesity drugs demand
-
-
-
-
-
-
-
Lilly becomes first drugmaker to hit $1 trillion valuation on weight-loss demand
-
-
-
-
-
-
-
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
-
1,198,739 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

